AIFsh, a novel apoptosis-inducing factor (AIF) pro-apoptotic isoform with potential pathological relevance in human cancer

被引:74
作者
Delettre, C [1 ]
Yuste, VJ [1 ]
Moubarak, RS [1 ]
Bras, M [1 ]
Lesbordes-Brion, JC [1 ]
Petres, S [1 ]
Bellalou, J [1 ]
Susin, SA [1 ]
机构
[1] Inst Pasteur, CNRS, URA 1961, F-75015 Paris, France
关键词
D O I
10.1074/jbc.M509884200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
AIF is a main mediator of caspase-independent cell death. It is encoded by a single gene located on chromosome X, region q25 - 26 and A6 in humans and mice, respectively. Previous studies established that AIF codes for two isoforms of the protein, AIF and AIF-exB. Here, we identify a third AIF isoform resulting from an alternate transcriptional start site located at intron 9 of AIF. The resulting mRNA encodes a cytosolic protein that corresponds to the C-terminal domain of AIF ( amino acids 353 - 613). We named this new isoform AIFshort (AIFsh). AIFsh overexpression in HeLa cells results in nuclear translocation and caspase-independent cell death. Once in the nucleus, AIFsh provokes the same effects than AIF, namely chromatin condensation and large scale ( 50 kb) DNA fragmentation. In contrast, these apoptogenic effects are not precluded by the AIF-inhibiting protein Hsp70. These findings identify AIFsh as a new pro-apoptotic isoform of AIF, and also reveal that the first N-terminal 352 amino acids of AIF are not required for its apoptotic activity. In addition, we demonstrate that AIFsh is strongly down-regulated in tumor cells derived from kidney, vulva, skin, thyroid, and pancreas, whereas, gamma-irradiation treatment provokes AIFsh up-regulation. Overall, our results identify a novel member of the AIF-dependent pathway and shed new light on the role of caspase-independent cell death in tumor formation/suppression.
引用
收藏
页码:6413 / 6427
页数:15
相关论文
共 51 条
[11]   Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms [J].
Glinsky, GV ;
Glinsky, VV ;
Ivanova, AB ;
Hueser, CJ .
CANCER LETTERS, 1997, 115 (02) :185-193
[12]   Efficiency comparisons of rank and permutation tests [J].
Good, PI .
STATISTICS IN MEDICINE, 2004, 23 (05) :857-857
[13]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[14]   The biochemistry of apoptosis [J].
Hengartner, MO .
NATURE, 2000, 407 (6805) :770-776
[15]   Anticancer therapy targeting the apoptotic pathway [J].
Hu, W ;
Kavanagh, JJ .
LANCET ONCOLOGY, 2003, 4 (12) :721-729
[16]   Multiple cell death pathways as regulators of tumour initiation and progression [J].
Jäättelä, M .
ONCOGENE, 2004, 23 (16) :2746-2756
[17]   Programmed cell death:: many ways for cells to die decently [J].
Jäättelä, M .
ANNALS OF MEDICINE, 2002, 34 (06) :480-488
[18]   Alternative splicing and programmed cell death [J].
Jiang, ZH ;
Wu, JY .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 220 (02) :64-72
[19]   Role of the heat shock response and molecular chaperones in oncogenesis and cell death [J].
Jolly, C ;
Morimoto, RI .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (19) :1564-1572
[20]   Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death [J].
Joza, N ;
Susin, SA ;
Daugas, E ;
Stanford, WL ;
Cho, SK ;
Li, CYJ ;
Sasaki, T ;
Elia, AJ ;
Cheng, HYM ;
Ravagnan, L ;
Ferri, KF ;
Zamzami, N ;
Wakeham, A ;
Hakem, R ;
Yoshida, H ;
Kong, YY ;
Mak, TW ;
Zúñiga-Pflücker, JC ;
Kroemer, G ;
Penninger, JM .
NATURE, 2001, 410 (6828) :549-554